Sleep disruption in patients with active and treated endogenous Cushing’s syndrome
Authors' conclusion
Patients with treated CS report improved sleep quality compared to those with active disease, but almost half of treated patients still report sleep challenges. The need for sleep medications, reported by one third of patients, was not different after CS treatment. Ongoing mood disturbances may play a role in persistent sleep disruption. Further work should focus on determinants of sleep impairments in treated CS patients.
Study context
- Population
- Patients with pituitary or adrenal Cushing's syndrome (CS) enrolled in an observational study; 104 pituitary, 9 adrenal; 94 female; mean age at diagnosis 43.9 ± 13.4 years
- Participants
- 113 patients
- Exposure
- Treated vs active CS
- Outcome
- NHP sleep score (lower = improved)
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Treated
29.6
mean · ± 30.2
Active
51.9
mean · ± 30.9
P = 0.0005
Observational data: associations, not effects.
Further findings
- CushingQoL sleep score · lower with Treated
- P = 0.015
- Often or always trouble sleeping, treated patients
- 41.5%
- Nottingham Health Profile (NHP) and CushingQoL pain scores · not lower with Treated; NHP and CushingQoL respectively
- P = 0.39 and 0.53
Medication for sleep, mood or pain
- Proportion taking medication not different, treated vs active
Correlates of sleep in treated CS
- Anxiety and depression correlated with worse sleep scores
Original publication
Sleep disruption in patients with active and treated endogenous Cushing’s syndrome. Pituitary. Published 9 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →